Company Profile
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Latest News
Revolution Medicines (RVMD) Wins FDA Review Milestone For Daraxonrasib In Pancreatic Cancer
Can Revolution Medicines (RVMD) Justify Its Valuation On Daraxonrasib Survival Data?
Revolution Medicines (RVMD) Stock Looks Fully Priced With Strong Returns But Weak Value Checks
Will FDA Priority Review for Daraxonrasib Redefine Revolution Medicines' (RVMD) Pancreatic Cancer Narrative?
FDA Accepts RVMD's Filing for Daraxonrasib in Pancreatic Cancer
| Sector | Healthcare |
| Industry | Biotechnology |
| Website | https://www.revmed.com |
| Audit Risk | 2 |
| Board Risk | 8 |
| Overall Risk | 7 |
| Market Cap | 40.23B |
| Forward P/E | -32.62 |
| Trailing Annual Div. Rate | 0 |
| Trailing Annual Div. Yield | 0.00% |
| Trailing EPS | -7.11 |
| Forward EPS | -5.8 |
| Book Value | 7.49 |
| Price-to-Book | 25.25 |
| Enterprise-to-EBITDA | -28.12 |
| Short Ratio | 4.41 |
| Earnings Date | 08/05/2026 |
| Earnings Call Date | 05/06/2026 |
| Earnings Average | -2.06 |
| Earnings Low | -2.34 |
| Earnings High | -1.89 |
| Revenue Average | 15.47M |
| Revenue Low | 0 |
| Revenue High | 250.00M |